Sun Pharmaceutical Industries Ltd

Resolution: Reclassification to Public

• Ordinary resolution to reclassify three promoter group entities to Public under Regulation 31A.
• Applicants: Sudhir V. Valia, Raksha Sudhir Valia, Krishna V. Valia; 4,31,75,371 shares (1.80%).
• Promoter Group: 54.48% to 52.68%; Public: 45.52% to 47.32%.
• No change in control, management, board, paid-up capital, or rights of other shareholders.
• Board approved on 22 May 2026; NOCs from BSE/NSE received on 06 Aug 2026.
• Voting via postal ballot/e-voting; cut-off 21 Aug 2026; voting 28 Aug–26 Sep 2026.
• Results announced on or before 29 Sep 2026.
• Applicants and related parties abstain; voting exclusion under Regulation 31A.
• Rationale: aligns classification with current status; applicants not involved in management.

Meeting Details

• Date: 01-Sept-2026
• Venue: Mumbai
• Meeting type: Physical; group and one-on-one
• Event/organiser: Ashwamedh – Elara India Dialogue 2026

Participants

• Company participants: management roles not disclosed

Purpose

• Purpose: schedule of analyst/institutional investor meeting

Additional Notes

• No UPSI disclosed; no recording/presentation details indicated

Litigation update

• Third Circuit affirms district court's summary judgment in Sun's favor in Lipitor antitrust case.
• Appellate Court also denies class certification.
• Matter substantially closes, subject to remedies available to plaintiffs.
• Litigation relates to a 2008 Lipitor settlement with Pfizer.
• No material financial liability arises at this stage.

Nidlegy EMA MAA resubmission update

• Nidlegy EMA MAA resubmission based on 33-month follow-up and new event-free survival analyses.
• The updated dossier includes longer follow-up and post-hoc analyses from the PIVOTAL Phase III study.
• PIVOTAL Phase III shows Nidlegy reduced relapse or death risk versus control; safety largely low-grade local AEs.
• Additional CMC information added to address questions raised during the previous regulatory procedure.
• Supporting data include Phase II PH-L19IL2TNF-02/12 and NeoDREAM safety data.
• Data accepted for publication in Journal of Clinical Oncology; online publication expected soon.
• Nidlegy is partnered with Sun Pharma for Europe, New Zealand and Australia.
• PIVOTAL enrolled 256 patients across 22 centers in Germany, Italy, France and Poland.
• Nidlegy is being developed as a neoadjuvant treatment for locally advanced, fully resectable melanoma.

Nidlegy EMA MAA update

• Philogen submitted an updated MAA to the EMA for Nidlegy neoadjuvant melanoma.
• Longer median follow-up of 33 months vs 21 months in prior submission.
• Post-hoc analyses focus on event-free survival.
• Annals of Oncology published data supporting 2024 submission; Journal of Clinical Oncology accepted.
• Updated dossier adds additional Chemistry, Manufacturing and Controls information.
• PIVOTAL Phase III study shows Nidlegy reduced relapse or death risk versus control.
• Nidlegy is partnered with Sun Pharma for Europe, New Zealand, and Australia.
• Safety profile described as largely low-grade, local adverse events.

Regulatory approval and product details

• SAHPRA approves a generic semaglutide injection for adults with type 2 diabetes in South Africa.
• Product to be launched as a pre-filled, multi-dose pen in 2 mg/1.5 mL and 4 mg/3 mL.
• Launch planned in coming days following approval.

Strategic context and market

• South Africa is Sun Pharma's second market after India for generic semaglutide.
• Approval supports expanded access to treatment and the company's generic development strategy.

Operational and governance notes

• Manufacturing and marketing authorization obtained; no leadership changes noted.

Meeting Details

• Virtual earnings conference call on 31 July 2026 at 06:30 pm IST.
• Results for the quarter ended 30 June 2026 to be discussed.
• Organised by Sun Pharmaceutical Industries Limited.
• Pre-registration via DiamondPass is required.

Participants

• Senior management to participate (e.g., CEO, CFO).

Purpose

• Discuss performance and answer investor questions.

Availability

• Transcript will be available on the Sun Pharma website.
• Audio webcast available; details to be announced on the website.

Meeting Details

• Board meeting scheduled for Friday, 31 July 2026 (time and venue undisclosed).

Key Agenda Items

• Consider and approve unaudited standalone and consolidated financial results for quarter ended 30 June 2026 and connected matters.

Other Notes

• Trading window closed from 01 July 2026 to 02 August 2026.